Core Insights - Mirxes, established in 2014, is a Singapore-based RNA biotechnology company focusing on early screening and diagnosis of high-incidence cancers globally, with a pipeline that also includes cardiovascular, metabolic, and infectious diseases [1] - The company's core product, MiXiaoWei, received regulatory approval in September 2025 as China's first non-invasive gastric cancer screening diagnostic tool, addressing a significant gap in early detection methods in the country [1] - The product utilizes proprietary RNA biomarker detection technology to analyze the relative content of 12 types of miRNA in blood serum samples, providing a precise screening method for high-risk gastric cancer populations [1] Product Performance - Clinical trials for MiXiaoWei involved approximately 10,000 participants, demonstrating a sensitivity of 85%, which effectively enhances the identification of early gastric cancer and precancerous lesions [2] - The negative predictive value of 99.4% significantly reduces the likelihood of false positives, thereby minimizing unnecessary follow-up examinations and alleviating the burden on healthcare resources and individuals [2] - MiXiaoWei has received multiple international approvals, including from the Singapore Health Sciences Authority, EU CE certification, FDA breakthrough device designation in the U.S., and approval from Thailand's FDA [2]